Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target

Biohaven Pharmaceutical (NYSE:BHVN) shares fell 1.9% to $15.40 in premarket trading after RBC Capital downgraded the company to Sector Perform from Outperform and lowered its price target to $19 from $23.

RBC based the downgrade primarily on valuation following a recovery in Biohaven's share price. According to the supplied information, the shares have risen approximately 100% from their 2026 lows and were up around 39% year to date.

The firm said the increase had made the risk-reward profile less favourable under its assessment of the stock.

RBC Assesses Opakalim Clinical Programme

RBC also considered Biohaven's clinical pipeline, including its Opakalim epilepsy programme.

The firm identified limited patient data and what it considers less-established clinical differentiation for Opakalim as factors contributing to its assessment of the programme's risk.

Those observations represent RBC's analysis and do not establish the outcome of Biohaven's ongoing clinical development programme.

Biohaven is approaching a Phase 3 data readout for Opakalim, which will provide further information on the investigational treatment.

SK Biopharmaceuticals Deal Added $400 Million

RBC acknowledged the impact of Biohaven's Kv7 licensing agreement with SK Biopharmaceuticals, which brought the company $400 million.

According to the bank, the transaction strengthened Biohaven's balance sheet and provided greater financial visibility ahead of forthcoming clinical readouts.

The supplied information also identifies Xenon Pharmaceuticals as a competitor in the epilepsy market. Xenon's Kv7 candidate, azetukalnar, is described as being at least two years ahead in development.

Some analysts have questioned whether Biohaven can achieve existing peak-sales consensus estimates without demonstrating sufficient clinical differentiation, according to the source material. These estimates remain forecasts rather than established future sales.

Biohaven Short Interest Stands at 13.6% of Float

Short interest in Biohaven represented approximately 13.6% of the company's float, according to the supplied information.

The shares traded lower alongside a weaker broader U.S. market, with the S&P 500 down 0.2% and the Dow Jones declining 0.7% in premarket trading.

At $15.40, Biohaven remained above its 52-week low of $7.48 and below its 52-week high of $18.57.

Investors are now awaiting the Phase 3 Opakalim data as they assess the company's epilepsy programme alongside its financial position following the SK Biopharmaceuticals licensing agreement.